New drug PORT-77 tested in humans for first time
NCT ID NCT06346509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety of a new drug called PORT-77 in 156 healthy adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moves through the body. The goal was to gather initial safety information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PORT-77
- What this could lead to
- If successful, this trial will provide initial safety data to support further testing of PORT-77 for potential future medical uses.
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, so it cannot show any treatment benefit. The drug may cause side effects or fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test